AlphAIAlphAI — Financial news for AI agents
investorideas.comOCT 202 min read$MYGN

Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business

Myriad Genetics (MYGN) shares rose 36.94% to $5.77 on news of selling its Prenatal Health testing business to Labcorp (LH) for $210M in cash. The deal, expected to close in early 2027, is projected to boost MYGN's revenue growth and profitability, according to the company. Labcorp anticipates $160M in revenue from the acquisition in its first year.

Original reporting
investorideas.com
Published Oct 20, 2026, 5:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 6:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Molecular Diagnostic Stock Myriad Genetics (NASDAQ: MYGN) Gains on News of Selling Prenatal Health Testing Business — source image
Source · investorideas.com
Decision brief

The 30-second read

$MYGNBullishHigh
01

Why it matters

The transaction provides Myriad with cash to fund its core oncology portfolio and gives Labcorp a broader women's health offering.

02

Market read

The deal is material for both companies, moves Myriad shares sharply higher, and adds revenue to Labcorp, making it a high‑impact M&A news item.

03

What to watch

Regulatory clearance risk and integration execution could delay expected revenue and earnings accretion for Labcorp.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Myriad Genetics is a molecular diagnostics company focusing on cancer genetics; Labcorp is a leading national laboratory services provider.

Company-level read

Ticker impact

$MYGNBullishHigh confidence
Context

Myriad Genetics announced a definitive agreement to sell its Prenatal Health testing business to Labcorp for $210 million in cash, driving a 36.9% intraday price surge.

Expected impact

likely upward pressure as the market prices in the cash proceeds and strategic focus on cancer diagnostics

Evidence & confidence

Deal size is material, cash component is sizable for a mid‑cap, and the stock already rallied sharply on the news.

$LHBullishMedium confidence
Context

Labcorp entered into a definitive agreement to acquire Myriad's Prenatal Health testing business for $210 million, adding an estimated $160 million of revenue in year one.

Expected impact

moderate upside as investors value the revenue boost and strategic fit

Evidence & confidence

Revenue add‑on is modest relative to Labcorp's scale, but the deal aligns with its growth strategy.

Market effects

Sector

Consolidates the reproductive genetics niche under Labcorp, potentially prompting further M&A activity in molecular diagnostics.

Regional

U.S. healthcare and diagnostics sector sees a positive reallocation of capital.

Global

Highlights continued strategic realignment in the global molecular diagnostics market.

Counterpoint

What could challenge this read

Some investors may view the divestiture as a signal that Myriad's prenatal segment underperformed, questioning long‑term growth prospects.

Key entities

  • Company
    Myriad Genetics

    Seller of the Prenatal Health testing business.

  • Company
    Labcorp

    Buyer of the Prenatal Health testing business.

Read at source← All news

StoryMyriad Genetics to sell its Prenatal Health unit to Labcorp for $210 million in cash

Also covered by

5 outlets

Related articles

OCT 20
$QGENMed

Qiagen Deal Chatter Lifted US Healthcare Stocks

EQT offered $50+ per share for Qiagen, raising its stock 5.8%. Labcorp agreed to buy Myriad Genetics' prenatal testing unit for $210M, boosting Myriad 36% and Labcorp 1%. GeneDx gained on sequencing plans. Investors focus on deal probabilities and sector-wide M&A expectations.

finimize.com2 min
OCT 20
$MYGNMed

TD Cowen holds Myriad Genetics stock rating on Labcorp sale

TD Cowen reiterated a Hold rating and $4.50 price target on Myriad Genetics (MYGN) after it agreed to sell its Prenatal Health business to Labcorp for $210M. MYGN shares trade at $5.76, with a market cap of $550M. The sale aims to simplify the company's portfolio and focus on Cancer Care Continuum. MYGN reported Q2 2026 revenue of $190.7M, down 11% YoY, missing estimates. Piper Sandler downgraded MYGN to Underweight with a $2 price target.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics stock surges on $210M prenatal unit sale

Myriad Genetics (MYGN) shares rose 36% after announcing a $210M sale of its prenatal testing unit to Labcorp (LH). The deal includes tests generating $160M in annual revenue. Myriad expects the sale to boost growth and profitability, while Labcorp anticipates added revenue and slight earnings accretion. The transaction is expected to close by early 2027, pending regulatory approval.

investing.com2 min
OCT 20
$MYGNHighAI 9/10

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Myriad Genetics (MYGN) shares rose 22.2% premarket after agreeing to sell its Prenatal Health business to Labcorp for $210M in cash plus inventory. The deal, expected to close by early 2027, includes a $10.5M reverse termination fee. The prenatal division had seen a 16% YoY revenue decline in Q2. CEO Sam Raha stated the divestiture will improve overall revenue growth and profitability.

financialcontent.com2 min
OCT 20
$MYGNHighAI 8/10

Myriad Genetics (MYGN) Shares Surge 20% Premarket on Prenatal He

Myriad Genetics (MYGN) shares rose 20% premarket after announcing the sale of its Prenatal Health division to Labcorp for $210M. Labcorp expects $160M in first-year revenue from the acquisition. MYGN's P/S ratio is 0.49, below historical and industry averages, reflecting market skepticism about growth. The company's GF Score is 47, indicating moderate financial health with weak growth and profitability.

gurufocus.com2 min
OCT 20
$LHMedAI 8/10

Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln

LabCorp (LH) will acquire Myriad Genetics' (MYGN) prenatal testing business for $210M in cash plus inventory value. The deal includes products like Prequel and Foresight. LabCorp expects $160M in revenue the first year and slight earnings accretion. Myriad plans to invest proceeds in cancer care. The transaction is expected to close by early 2027.

rttnews.com2 min